Results : This systematic review will provide a detailed summary of present evidence related to the efficacy and safety  of etoricoxib for patients with AS .
Conclusion : The results of this study may provide management guidance for AS treated by etoricoxib .
Background : Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis ( AS ) effectively .
However , no study systematic ally investigated the efficacy and safety of etoricoxib for patients with AS .
In this systematic review , we will assess the efficacy and safety of etoricoxib for AS .
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis
Objective : The combined efficacy of selective and non-selective cyclo-oxygenase-2 ( COX-2 ) inhibition on the axial manifestations of ankylosing spondylitis ( AS ) in the presence or absence of chronic peripheral arthritis was evaluated . Methods : In a post hoc subgroup analysis of a 6 week , r and omised , double blind , placebo controlled trial , 387 patients with active axial AS were r and omised to receive etoricoxib 90 mg or 120 mg once a day , naproxen 500 mg twice daily , or placebo . R and omisation was stratified by the presence or absence of chronic peripheral arthritis . The primary outcome measure was the time weighted average change from baseline of spine pain intensity . Efficacy data from the three groups receiving active treatment ( the NSAID/COX-2 inhibitor group ) were combined to improve precision . An analysis of covariance model was used to evaluate the effect of peripheral disease on treatment response . Results : 93 patients were allocated to receive placebo and 294 to active treatment ( naproxen or etoricoxib ) . The combined NSAID/COX-2 inhibitor group had a significant treatment response compared with the placebo group for all efficacy measures , both in patients with and without peripheral arthritis . A significantly greater difference in mean patient assessment of spine pain was found between active and placebo treatments in patients without compared with those with peripheral arthritis ( p = 0.005 ; −32.5 mm v −17.0 mm , respectively ) . Similar differences , although not statistically significant , were seen for other end points . Conclusion : NSAIDs and COX-2 inhibitors have a clinical ly relevant symptomatic effect on axial AS irrespective of the presence of peripheral arthritis . In this exploratory analysis spinal improvement appeared to be greater in patients without peripheral disease
Results : This systematic review will provide a detailed summary of present evidence related to the efficacy and safety  of etoricoxib for patients with AS .
Conclusion : The results of this study may provide management guidance for AS treated by etoricoxib .
Background : Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis ( AS ) effectively .
However , no study systematic ally investigated the efficacy and safety of etoricoxib for patients with AS .
In this systematic review , we will assess the efficacy and safety of etoricoxib for AS .